CD82 and prostate cancer: Decreased KAI1/CD82 expression has been observed to correlate with metastasis and poor prognosis in many human solid tumors, such as prostate cancer [27], lung cancer [28], breast cancer [29], colon cancer [30], gastric cancer [31], liver cancer [32], and kidney cancer [33].